TY - JOUR
T1 - Effects of unplanned treatment interruptions on HIV treatment failure - results from TAHOD
AU - The TREAT Asia HIV Observational Database (TAHOD)
AU - Jiamsakul, Awachana
AU - Kerr, Stephen J.
AU - Ng, Oon Tek
AU - Lee, Man Po
AU - Chaiwarith, Romanee
AU - Yunihastuti, Evy
AU - Van Nguyen, Kinh
AU - Pham, Thuy Thanh
AU - Kiertiburanakul, Sasisopin
AU - Ditangco, Rossana
AU - Saphonn, Vonthanak
AU - Sim, Benedict L.H.
AU - Merati, Tuti Parwati
AU - Wong, Wingwai
AU - Kantipong, Pacharee
AU - Zhang, Fujie
AU - Choi, Jun Yong
AU - Pujari, Sanjay
AU - Kamarulzaman, Adeeba
AU - Oka, Shinichi
AU - Mustafa, Mahiran
AU - Ratanasuwan, Winai
AU - Petersen, Boondarika
AU - Law, Matthew
AU - Kumarasamy, Nagalingeswaran
AU - Mean, C. V.
AU - Khol, V.
AU - Zhao, H. X.
AU - Han, N.
AU - Li, P. C.K.
AU - Lam, W.
AU - Chan, Y. T.
AU - Saghayam, S.
AU - Ezhilarasi, C.
AU - Joshi, K.
AU - Gaikwad, S.
AU - Chitalikar, A.
AU - Wirawan, D. N.
AU - Yuliana, F.
AU - Imran, D.
AU - Widhani, A.
AU - Tanuma, J.
AU - Nishijima, T.
AU - Na, S.
AU - Kim, J. M.
AU - Gani, Y. M.
AU - David, R.
AU - Syed Omar, S. F.
AU - Ponnampalavanar, S.
AU - Azwa, I.
N1 - Publisher Copyright:
© 2016 John Wiley & Sons Ltd.
PY - 2016/5/1
Y1 - 2016/5/1
N2 - Objectives: Treatment interruptions (TIs) of combination antiretroviral therapy (cART) are known to lead to unfavourable treatment outcomes but do still occur in resource-limited settings. We investigated the effects of TI associated with adverse events (AEs) and non-AE-related reasons, including their durations, on treatment failure after cART resumption in HIV-infected individuals in Asia. Methods: Patients initiating cART between 2006 and 2013 were included. TI was defined as stopping cART for >1 day. Treatment failure was defined as confirmed virological, immunological or clinical failure. Time to treatment failure during cART was analysed using Cox regression, not including periods off treatment. Covariables with P < 0.10 in univariable analyses were included in multivariable analyses, where P < 0.05 was considered statistically significant. Results: Of 4549 patients from 13 countries in Asia, 3176 (69.8%) were male and the median age was 34 years. A total of 111 (2.4%) had TIs due to AEs and 135 (3.0%) had TIs for other reasons. Median interruption times were 22 days for AE and 148 days for non-AE TIs. In multivariable analyses, interruptions >30 days were associated with failure (31-180 days HR = 2.66, 95%CI (1.70-4.16); 181-365 days HR = 6.22, 95%CI (3.26-11.86); and >365 days HR = 9.10, 95% CI (4.27-19.38), all P < 0.001, compared to 0-14 days). Reasons for previous TI were not statistically significant (P = 0.158). Conclusions: Duration of interruptions of more than 30 days was the key factor associated with large increases in subsequent risk of treatment failure. If TI is unavoidable, its duration should be minimised to reduce the risk of failure after treatment resumption.
AB - Objectives: Treatment interruptions (TIs) of combination antiretroviral therapy (cART) are known to lead to unfavourable treatment outcomes but do still occur in resource-limited settings. We investigated the effects of TI associated with adverse events (AEs) and non-AE-related reasons, including their durations, on treatment failure after cART resumption in HIV-infected individuals in Asia. Methods: Patients initiating cART between 2006 and 2013 were included. TI was defined as stopping cART for >1 day. Treatment failure was defined as confirmed virological, immunological or clinical failure. Time to treatment failure during cART was analysed using Cox regression, not including periods off treatment. Covariables with P < 0.10 in univariable analyses were included in multivariable analyses, where P < 0.05 was considered statistically significant. Results: Of 4549 patients from 13 countries in Asia, 3176 (69.8%) were male and the median age was 34 years. A total of 111 (2.4%) had TIs due to AEs and 135 (3.0%) had TIs for other reasons. Median interruption times were 22 days for AE and 148 days for non-AE TIs. In multivariable analyses, interruptions >30 days were associated with failure (31-180 days HR = 2.66, 95%CI (1.70-4.16); 181-365 days HR = 6.22, 95%CI (3.26-11.86); and >365 days HR = 9.10, 95% CI (4.27-19.38), all P < 0.001, compared to 0-14 days). Reasons for previous TI were not statistically significant (P = 0.158). Conclusions: Duration of interruptions of more than 30 days was the key factor associated with large increases in subsequent risk of treatment failure. If TI is unavoidable, its duration should be minimised to reduce the risk of failure after treatment resumption.
KW - Adverse events
KW - Antiretroviral
KW - Asia
KW - HIV
KW - Treatment interruptions
UR - http://www.scopus.com/inward/record.url?scp=84963722410&partnerID=8YFLogxK
U2 - 10.1111/tmi.12690
DO - 10.1111/tmi.12690
M3 - Article
AN - SCOPUS:84963722410
SN - 1360-2276
VL - 21
SP - 662
EP - 674
JO - Tropical Medicine and International Health
JF - Tropical Medicine and International Health
IS - 5
ER -